| AS | P-value | PsA | P-value | ||
---|---|---|---|---|---|---|
MI Cases | Controls | MI Cases | Controls | |||
Subjects, n | 237 | 894 | Â | 404 | 1596 | Â |
Female, n (%) | 110 (46.4%) | 406 (45.4%) | 0.7836 | 167 (41.3%) | 660 (41.4%) | 0.9951 |
Age, mean +/− SD | 63.0 +/−  11.3 | 62.8 +/− 11.0 | 0.7100 | 61.5 + −  11.2 | 61.4 + −  11.2 | 0.8300 |
Chronic kidney disease, n (%) | 13 (5.5%) | 36 (4.0%) | 0.3269 | 22 (5.4%) | 45 (2.8%) | 0.0088 |
Diabetes, n (%) | 62 (26.2%) | 191 (21.4%) | 0.1152 | 138 (34.2%) | 329 (20.6%) | < 0.0001 |
Ischemic heart disease, n (%) | 66 (27.8%) | 131 (14.7%) | < 0.0001 | 100 (24.8%) | 209 (13.1%) | < 0.0001 |
Liver disease, n (%) | < 11a (< 5.0%) | 22 (2.5%) | NSa | 20 (5.0%) | 58 (3.6%) | 0.2221 |
Peptic ulcer disease, n (%) | 58 (24.5%) | 233 (26.1%) | 0.6186 | 71 (17.6%) | 297 (18.6%) | 0.6316 |
Psoriasis, n (%) | 42 (17.7%) | 173 (19.4%) | 0.5697 | 259 (64.1%) | 1073 (67.2%) | 0.2347 |
Rheumatoid arthritis, n (%) | 76 (32.1%) | 237 (26.5%) | 0.0891 | 99 (24.5%) | 340 (21.3%) | 0.1649 |
Body mass index > 30 kg/m2), n (%) | 33 (13.9%) | 104 (11.6%) | 0.3365 | 75 (18.6%) | 201 (12.6%) | 0.0019 |
Statin use, n (%) | 95 (40.1%) | 308 (34.5%) | 0.1075 | 147 (36.4%) | 565 (35.4%) | 0.7118 |
Smoking status, n (%) | 28 (11.8%) | 54 (6.0%) | 0.0023 | 41 (10.1%) | 76 (4.8%) | < 0.0001 |
Rheumatology visit in year prior to diagnosis, n (%) | 103 (43.5%) | 406 (45.4%) | 0.8200 | 214 (53.0%) | 911 (57.1%) | 0.0200 |
ESR/CRP ordered in year prior to diagnosis, n (%) | 95 (40.1%) | 349 (39.0%) | 0.7693 | 175 (43.3%) | 651 (40.8%) | 0.3567 |